Mutations in BRCA1 tumor suppressor account for ~45% of hereditary breast cancer and predispose individuals to ovarian and prostate tumorigenesis. BRCA1-deficient cells contain numerous chromosome aberrations (duplications, translocations, inter-sister gaps) and defects in gene regulation. While BRCA1 binds numerous factors to engage in a wide variety of activities (ubiquitin ligase, DNA repair/damage signaling, chromatin remodeling, transcription activation), how BRCA1 mutations affect genetic instability at the molecular level remains unclear. 1, 2 Expressing the C-terminal BRCT domain of BRCA1 in budding yeast severely limits cell growth. This small colony phenotype revealed a physiological role for BRCA1 function even in this simple eukaryote and provided for rapid characterization of clinically relevant BRCA1 alleles. 3, 4 Subsequent yeast cell studies linked BRCA1 responses to DNA damage-induced stalled transcription complexes. 5, 6 However, a direct role for BRCA1 defects in promoting chromosomal instabilities has yet to be demonstrated.
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To identify novel yeast genes that participate in BRCA1 phenotypes, the C-terminal BRCT domain of BRCA1 (herein termed BRCA1) was transformed into a collection of yeast mutant strains representing a diverse array of cell processes. 7 From this collection, mutations in five genes (MCM21, CTF19, CTF7, TOF1 and CDC6) produced BRCA1-dependent conditional synthetic lethality (Fig. 1) . The first four genes reveal a novel link between BRCA1 and factors integral to chromosome segregation. Mcm21p and Ctf19p form part of the COMA outer kinetochore plate complex that promotes full kinetochore assembly. 8 Kinetochores tether chromosomes to spindle microtubules and produce chromosome motion during mitosis. Ctf7p (Eco1p) and Tof1p both promote sister chromatid pairing (cohesion)-a fundamental component of proper chromosome segregation. [9] [10] [11] Intriguingly, DNA damage activates Ctf7p-dependent cohesion which then promotes DNA repair. 10, 11 Consistent with the identification of ctf7 and tof1, we also found that smc3 mutants exhibit severely compromised growth when expressing BRCA1 (data not shown). Smc3p is a structural cohesin component that maintains sister chromatid pairing from S-phase until anaphase. 9 The fifth gene, CDC6, promotes DNA replication initiation. Cdc6p is recruited by Origin Recognition Complexes (ORCs) which subsequently bind MCM helicase to form a DNA pre-replicative complex (pre-RC). 12 Chl1p is a DNA helicase that functions in sister chromatid-pairing reactions. 10 Chl1p was of interest because its human homolog BACH1/ BRIP/FANCJ binds BRCA1. 13, 14 We quantified colony diameters of wildtype and chl1 cells expressing either BRCA1 or mutant brca1 (nonsense mutation producing a truncated protein) after 3 days at 30°. Wildtype cells expressing BRCA1 produced an average colony diameter 39% (41% upon independent assay) the size of cells expressing the mutated brca1 control. chl1 cells containing the mutant brca1 control produced an average colony diameter 73% (79% upon independent assay) the size of wildtype cells containing mutant brca1, revealing a chl1-dependent small colony phenotype. If not lethal, the combination of BRCA1 and chl1 should produce greatly diminished colony diameters. Instead, chl1 cells expressing BRCA1 produced an average colony diameter 50% larger (31% upon independent assay) than expected and surprisingly larger than wildtype/BRCA1 colony diameters. Parallel studies similarly revealed that chl1 cells expressing BRCA1 produce an average colony diameter ~20% larger than expected when compared to a random control vector (Suppl. data).
Here, we report that BRCA1 function specifically perturbs kinetochore and cohesion pathways-possibly by altering assembly/ dissolution reactions, respectively. This model is supported by evidence that BRCA1 predominantly localizes to heterochromatic centromeric DNA upon which both kinetochores and cohesins assemble. 15 Of the six genes identified in this study, Ctf7p and Chl1p are of particular interest. Yeast and human Ctf7 (EFO2/ESCO2) and human BRCA1 share many binding partners (RFC, PCNA, helicases) that can exhibit acetyltransferase-related activities. 1, 9 Defects in human EFO2/ESCO2 (and hSMC3) produce a variety of maladies including SC phocomelia, Roberts syndrome and Cornelia de Lange syndrome. 10, 16 In humans, BACH1/BRIP/FANCJ (Chl1p in yeast) binds and participates in BRCA1-dependent DNA double-strand break repair. 10, 13 Notably, chl1 interacts genetically with each of ctf7, tof1, ctf19 and mcm21, 14, 17, 18 suggesting that Chl1p links BRCA1 to kinetochore/cohesion activities. We further speculate on how BRCA1 exacerbates cdc6-dependent alleles. Previous findings suggest that Ctf7-dependent cohesion establishment is coupled to DNA replication. 9 Thus, BRCA1 may uncouple establishment from replication initiation in cdc6 mutants. Alternatively, Cdc6p binds ORCs which maintain sister chromatid pairing in parallel to cohesins, 19 suggesting that BRCA1 effects ORC-dependent sister chromatid pairing. Colony size after 7 days of growth at 30°. Lethality was also observed in ctf19, mcm21 and cdc6 mutant strains expressing BRCA1 at 12° (Suppl. data). Note that the extended periods of growth chosen to highlight BRCA1-dependent lethality negate the small colony phenotype. Field of view = 53 mm. (C) Loss of CHL1 partly rescues this growth defect. Independent assays reveal that chl1 cells expressing BRCA1 produce colony diameters roughly 40% larger than the expected small colony phenotype (red arrow) and larger than wildtype cells expressing BRCA1, compared to a truncated brca1 control plasmid.
